Visit the News Hub

This episode of Show Me the Science' focuses on racial disparities in COVID-19, as well as protests aimed at systemic racism

Wenners Ballard III, MD, a hospitalist and an instructor in the Department of Medicine, took part in the White Coats for Black Lives demonstration on the Washington University Medical Campus in June. Ballard is providing for acutely ill patients who are hospitalized with COVID-19.

A new episode of our podcast, Show Me the Science, has been posted. At present, these podcasts are highlighting research and patient care on the Washington University Medical Campus as our scientists and clinicians confront the COVID-19 pandemic.

In St. Louis, as in much of the United States, African Americans are more likely to test positive for COVID-19. Theyre also more likely to be hospitalized, to end up in intensive care and to die of the infection. Further, protests that have erupted against police violence point to another stressor shouldered primarily by African Americans.

Lee

In this episode, we discuss systemic racism inside and outside the health-care system and how the COVID-19 pandemic has propelled the issue to the forefront of our national consciousness. We speak with third-year medical student Kamaria Lee about her life as she studies to become a doctor during a time of massive protests and a pandemic. We also speak with Wenners Ballard III, MD. A hospitalist and an instructor in the Department of Medicine, he takes care of acutely ill patients in the hospital. These days, every one of his patients has been hospitalized for COVID-19. The majority also are people of color.

The podcast Show Me the Science is produced by the Office of Medical Public Affairs at Washington University School of Medicine in St. Louis.

[music plays]

Jim Dryden (host):Hello and welcome to Show Me the Science, a podcast about the research, teaching and patient care, as well as the students, staff and faculty at Washington University School of Medicine in St. Louis, Missouri, the Show Me State. My name is Jim Dryden, and Im your host this week. Weve been focusing these podcasts on the COVID-19 pandemic and Washington Universitys response. This week, we focus on race. In the St. Louis region, African Americans are four times more likely than members of other racial and ethnic groups to test positive for the coronavirus. And, as is the case in other parts of the country, theyre also more likely to be hospitalized, to be sent to an intensive care unit, and to die from the infection. But as weve all been reminded recently through the deaths of George Floyd, Breonna Taylor, Rayshard Brooks and others, COVID-19 isnt the only public-health issue having an impact on people of color. Well speak this week about race, public health, COVID and public demonstrations with third-year medical student Kamaria Lee.

Kamaria Lee:There is this decision that people, both inside and outside the Black community, are making of what is worse: putting myself out there and potentially getting COVID, or being silent. Everybody is still afraid, especially when we have had episodes of tear gas being sprayed, and people then are coughing and tearing and rubbing their eyes. So the fear isnt going to go away, but some people are saying, Enough is enough, and theyre kind of putting down their COVID fears to go out and protest.

Dryden:In fact, Washington University faculty, students and staff were recently among those at a White Coats for Black Lives event at the Washington University Medical Campus. Heres hospitalist Wenners Ballard.

Wenners Ballard III, MD:Were not going to stand for this. Enough is enough. And I think when you see health-care professionals, people that a lot of time you will put your life in their hands, standing up for a particular cause, it can resonate with people in a different way. And I think that touched me the most because a lot of times, you can feel like the world is against you and nobody does care. It touched people that saw the demonstration. And thats why we did it.

Dryden:In the earliest days of the COVID-19 pandemic, as it was becoming obvious that African Americans were getting sick and dying at very high rates, medical student Kamaria Lee, who is hoping to pursue health inequities research after she graduates, wrote about the viruss effects on the Black community, and in that essay, she said, Each time I lose more of my people, I lose a part of me.

Lee:There has been somewhat of a narrative in our idea that Blacks are perhaps inherently more unhealthy. But its a narrative thats tied to Blacks having a higher rate of chronic conditions. Its this idea that Blacks are more likely to have the whole list: hypertension or diabetes and things like that. And thats really offensive when that is used as the rationale or the reason why there is a higher death rate in the Black community in St. Louis and across the country. Because a lot of that is said with this blame on the Black community, that its our fault that were just inherently unhealthy, that we could have made better choices. When really, you have to look again at history, you have to look at systemic racism and say, What is it like to undergo racism and discrimination on a daily basis? How is it possible for someone, whether its microaggressions or something more overt, to experience these things chronically throughout their life and have it not affect their health? It does. It affects your health. It has this extra load on your body. And all of that affects baseline level of health, and then it also can be amplified as were seeing in a pandemic or with many other illnesses.

Dryden:And I want to know how thats affected you as you are pursuing your training.

Lee:Being a medical student and knowing that the data is out there, that Blacks have a higher death rate, are more likely to be hospitalized and infected with COVID-19, and also already having experienced what its like to be a Black medical student. There arent many Black students in higher education in general, and thats true in medical training as well. So already having experienced, what it feels like a special bond with the Black patients that Ive interacted with in the hospital due to a cultural congruence, perhaps in some cases, but not all, increased trust. And then hearing about this public health crisis, or rather living through this public health crisis, knowing that its those patients or patients who look like me who Ive already related to on a very deep level in the hospital that are some of those that are most affected. Even just the anxiety and the mental-health aspect of knowing that your community is being more affected is also something that theyre going through and a struggle that we share.

Dryden:And you wrote youve seen extra fear in your peoples eyes when theyre in the hospital and there are few, if any, clinicians who look like them. So you also say that you felt distrust even of you sometimes because, for some, that white coat makes you a part of the ivory tower. I want to know, can you talk a little bit more about that?

Lee:Yeah. I think its important to always know the historical context in which were working. Even for myself being a part of the community, educating myself on what happened before I was here. And so just looking back, we have, from the 1930s to the 1970s, the Tuskegee syphilis study, in which Black men were experimented on in order to see what would happen with untreated syphilis. So during that time, penicillin was seen to be a cure for syphilis, but the men were not told about that, and their syphilis continued to be untreated, which is completely unethical and horrifying. There are also instances of Black bodies being robbed from graves to be used during medical dissections historically. And so not everyone in the Black community knows all of this historical detail. Some do, but some of that history is a part of the distrust. Or even more recently, segregation hospitals or knowing that your life isnt seen as the same when you walk into the health-care system because you were taken to a different hospital and some clinicians wouldnt allow you into their clinic. So all of that has created a long history and a reasonable history of distrust of, yeah, white clinicians, non-Black clinicians, but also the system. And a part of me being a clinician means that my identity is multiple things. Im a Black woman, but Im also part of the health-care system. And so sometimes skin color or even the same culture, a similar background, isnt enough to kind of negate the distrust that, like I said, is rightfully there for many reasons.

Dryden:Is this a good time to be a medical student? I mean, obviously the pandemic affects the rotations that you can do, your interaction with patients. On the other hand, this is a once-in-a-century sort of public-health crisis combined now with a public-health crisis thats been going on in the United States for at least 400 years.

Lee:Going to medical school now with the COVID-19 pandemic and with the current changes that were seeing, more people in society want to make towards or against racism. I think a lot of people in the Black community and other minority communities have been pushing for people to realize how bad racism is, which sounds silly because its been going on for decades and hundreds of years. But I feel like there has been this hope for others and enough of other people to finally be fired up to make change. And I think that while its not changing everyones minds and some people are more cynical about how much change can actually be made, I think its a critical moment for people in medical school to understand that you need to acknowledge racism and be actively working against racism in order to be an adequate clinician.

Dryden:When you finish medical school, somebodys going to make a speech and say to you and your classmates that youre part of the future, you will write the future. But you wrote in your essay that its hard not to be intimidated by the enormity of the problem here. So how can you and your classmates make that future different and better?

Lee:One thing I recently encouraged my classmates to do is to all put health inequity research as something that they do. Or if theyre interested in research, health equity advocacy is something that they do. I have a bachelors in sociology from college. And like I said, right now and in the future, I hope to continue health inequities research. And while its great that I can define myself that way and say, This is who I want to be in my academic career, its actually sad that I can define myself that way because it should just be something that all clinicians are doing. It shouldnt be a distinguishing factor. It should be, Im in the medical field. Ive taken an oath. And Im here to fight against inequities, fighting against racisms effects on health. And so thats something that I really hope my classmates will all do, is define themselves the same way I have defined myself so that its not actually a unique way to go about their careers.

Dryden:Several WashU physicians, others recently, that participated in the White Coats for Black Lives. What message was sent that day, and does it relate in any way to the inequities that you see regarding COVID-19?

Lee:I think it represents an intent, it represents an action. But as far as how large the issue is of racism and how significant racism is as a threat to public health, as weve seen with the police brutality or just several unjust murders, its a very small step. It is up to everyone, regardless of their race or ethnicity or their own background or privilege, to walk in what they did at the protests every single day. To be more cognizant of how they are treating their patients, to understand, Maybe if Im not from the same culture, that doesnt mean there is no chance of relating, and so to at least try. There is a lot of things that need to happen in the micro-level within each patient interaction, with interactions of all of their trainees, as well as in their own personal lives and how they raise their children. And so something thats a powerful image can represent intent and hopefully represents a promise. But its a very small step in what actually needs to be done both by individuals and at institutional levels. But some people are saying, Enough is enough and are kind of putting down their COVID fears to go out and protest.

Dryden:One of those young African Americans wearing a white coat was Wenners Ballard III. Hes a hospitalist at Washington University and Barnes-Jewish Hospital in St. Louis. That means he takes care of acutely ill patients in the hospital. And for the last several weeks, that has meant patients who have COVID-19.

Ballard:Ever since this really ramped up in about late February or early March, Barnes dedicated a certain group of physicians to only taking care of COVID patients to sort of limit the exposure to a lot of physicians. And I was one of those.

Dryden:Is that a scary thing from your perspective, or does it mean that there are certain folks in your life that you cant see because youre taking care of these patients?

Ballard:I dont know if I would call it scary. Its definitely in the back of your head where you do hear of younger people catching this and having poor outcomes. But its definitely a lower mortality rate in people in my demographic age group-wise. But it is still worrisome. And I wasnt able to my dad has multiple myeloma and hes currently on chemotherapy, so I wasnt able to go back and see him, where I probably otherwise would have. So in that way, it did affect me. But you kind of put all that to the side when you see how many people are affected and kind of need your help. It just feels like your calling and this is what you did all this for in the first place. So you kind of step up to the plate and dont really think about the other things.

Dryden:African Americans have been hit harder than many other communities. Is that what youve experienced on the floors at Barnes-Jewish?

Ballard:Absolutely. Definitely, African Americans have been hit disproportionately by COVID, especially in St. Louis. I think when you look at the statistics across the nation, what youre seeing is African Americans being disproportionately affected, but specifically African Americans that live in certain parts of the country. So for instance, if you look at New York, which is kind of the epicenter for all of this, people that lived in certain counties in New York City had a threefold higher rate of infection and a sixfold higher rate of dying. If you look in cities like Chicago thats much closer, the infection rate among African Americans, I believe, was around 50%

Dryden:Meaning that 50% of the COVID cases in Chicago involved African Americans.

Ballard: And the mortality rate among African Americans was around 70%, but they only make up 30% of the population in Chicago. Its mostly centered around on the south side of Chicago. So it has a lot to do with socioeconomic status.

Dryden:These racial disparities are not unique to COVID-19, correct?

Ballard:They are not. And I think its interesting I was actually thinking about this the other day I think COVID-19 kind of pulled back the shade a little bit and showed us like, Wow, these health disparities are real, and theres something that really needs to be done about it. Sort of like how when everybody saw that video of the knee on his neck, people said, Wow, enough is enough. Theres something that we need to do about it. And youre seeing some change occur already. I hope that same thing will happen in the health-care community and we start to do more things to try to bridge the gap. When you arent able to do social distancing because you work at the local grocery store, you work at the gas station, you work at places where youre not able to work from home, youre not able to telework, youre not really able to social distance. And also, when you live in these areas, the household density is higher, meaning theres a lot more people under one roof. And I think St. Louis is a prime example, when you look at the Delmar Divide, weve known about these health-care disparities for a very long time. I had a lady that was 50 years old. She had no medical co-morbidities. And she could not stop going to work because if she did, her lights would be cut off, her waters going to get cut off. She got COVID. She ended up on the highest form of life support we had called ECMO. Ultimately, she did walk out of the hospital. And she is one of the very rare cases that we see. And she almost didnt make it. And its just very shocking to see a 50-year-old thats otherwise very healthy that probably could have avoided this if she could have teleworked, if she had been able to not worry about her lights, if she had, you know, a lot of things.

Dryden:What can medical professionals and the health-care community in general do about this at the moment? Well, you know, on the George Floyd issue, we can say, Well, lets take some steps to monitor police in different ways. On the health-care front, what can someone like you do?

Ballard:Its complicated, and its going to take a lot and a long time, but I think what we can start doing right now is working on our own implicit biases, kind of addressing how we look at each individual patient. So I know a lot of times colleagues of mine walk into a room and see a particular patient and adjust the way they speak to them or adjust their expectations of how that interaction is going to go. I think sometimes people and I dont think people do it maliciously, honestly. I think its just because of lack of knowledge and lack of exposure. I dont think people should be ashamed to say that they dont really know how to go about these interactions or how to make sure somebody is understanding what theyre saying. Educating our patients more is a big part of this. Thats something that we can do every day when we walk into a patients room. And I think doing our best to check our biases at the door is another big thing that we can do right now. I mean, its something that we definitely need to start doing, but we also need to work on a bigger change in the country overall.

Dryden:You recently attended the White Coats for Black Lives event. What motivated you to do that? And what message were you, and the other physicians and health-care workers participating trying to send?

Ballard:I think the message that were trying to send is, overall, one, solidarity and unity and standing up for whats right and showing the people in this country and the rest of the world that were not going to stand for this, enough is enough. And I think when you see health-care professionals, people that a lot of times you will put your life in their hands, standing up for a particular cause, it can resonate with people in a different way. And I think, when I saw a lot of the people driving by, it was very interesting to see the varying reactions. There were some people in tears just being so touched by it, some people honking their horns, clapping, cheering. Some people scowling. Some people yelled out some things as they drove by. What I saw overall was overwhelming support. And I think that touched me the most. Because a lot of times you can feel like the world is against you and nobody does care, but to see that amount of people in that position caring that much, that they walk out of their jobs, they stand on the street, they hold up signs, they kneel for 8 minutes and 46 seconds, to see that many people doing that in that profession, it touched me. So I know that it touched people that saw the demonstration. And thats why we did it. We did it to show that this cant keep happening and its not going to keep happening and were going to do something about it.

Dryden:People were wearing masks. They were socially distancing. When you see some of the other protests where maybe masks arent as ubiquitous and where maybe people either by choice or because theyve sort of been corralled by police are very close together, does that worry you as the guy that might be treating some of these folks?

Ballard:Absolutely. Absolutely. Because of course, a lot of the people at these protests are 50 and younger. You would probably be asymptomatic if youve got it, honestly, or have mild symptomatology from it, but you could pass it on to somebody thats not. So I think it is important that people do, especially for the time being, keep their masks on. Especially at these protests, we get really excited, were loud, I think it is important to try to social distance as best you can and wear a mask. And if you do that, then dont let it deter you, and get out there. Get your message across. Thats also important because theyre both health-care crises.

[music plays]

Dryden:Ballard and Lee say many things must change to address the health-care disparities that put people of color at greater risk for COVID-19 and other illnesses. And both say theyre committed to becoming part of the solution and encouraging their colleagues in medicine to do the same. Show Me the Science is a production of the Office of Medical Public Affairs at Washington University School of Medicine in St. Louis. The goal of this project is to keep you informed and maybe teach you some things that will give you hope. Thanks for tuning in. Im Jim Dryden. Stay safe.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

See the original post here:

Podcast: Racism as a public health issue - Washington University School of Medicine in St. Louis

By RYAN MCCRACKEN on June 26, 2020.

rmccracken@medicinehatnews.com

When Ken Holland picked up his phone Wednesday to find Lanny McDonald was calling, he was initially a bit confused.

However, it didnt take long for Holland to realize that the only Medicine Hat Tigers alumnus ever inducted into the Hockey Hall of Fame was calling for a reason hes no longer the only one.

Briefly I was wondering why Lanny called, then I got the news. Lanny told me I was one of the newest members of the Hockey Hall of Fame, Holland said in a Wednesday conference call with media. Really, it hasnt sunk in yet, and I think its going to take a while to sink in. I think back to growing up in Vernon, B.C. and playing minor hockey and Tier 2 junior hockey. I really was just a backup goalie in Tier 2 and made the Medicine Hat Tigers, and then today to get the call that Im going into the Hockey Hall of Fame. You think about all the great people, the great players and all the great people who have played the game, and what a wonderful game this is.

Holland now working as general manager and president of hockey operations with the Edmonton Oilers was inducted as a builder alongside players Jarome Iginla, Marian Hossa, Kevin Lowe, Kim St. Pierre and Doug Wilson.

McDonald has been playing Santa Claus by making calls to induct hockeys all-time greats ever since being named HHOFs chairman of the board in 2015, but Wednesday was the first time it had him recalling his years in Medicine Hat alongside another former Tabby.

Medicine Hat was probably the best time of my life, said McDonald, who racked up 112 goals and 141 assists as a member of the Tigers from 1971-73, and became the first player in team history to have his number retired. Medicine Hat had such a great following of fans, and in the second year to be able to go to the Memorial Cup was pretty phenomenal. I met my dear wife, Ardell. Weve been married now for 45 years, so I owe a lot to Medicine Hat.

Its a feeling shared by Holland as well. The 64-year-old Vernon product also met his wife, Cindi, while competing with the Tigers, and says his experiences in the Gas City helped shape his future in the game.

Im like, Lanny, those were two of the greatest years of my life,' said Holland. It really was the opportunity for me to start my career. If I didnt make the Medicine Hat Tigers I would never have had an opportunity to go on and play pro hockey for nine years and meet the people I did along the way.

After earning a place on Medicine Hats roster for the 1974-75 season, Holland went on to record a 4.05 goals against average over two years and 78 games with the club before moving into a nine-year professional career.

It was certainly a springboard for me to be able to go on and play pro hockey, then to stay in the game once my career ended, said Holland. Some of the players that I played with (in Medicine Hat) are still some really good friends of mine today Don Murdoch, Brian Hill, Gary Gilchrist, Ron Areshenkoff, who was in my wedding party and unfortunately just passed here a few months ago.

It was after hanging up his skates following 343 games in the American Hockey League as well as stints in the NHL and International Hockey League that Holland shifted his focus to the management side. But he almost ended up selling vacuums.

I played nine years of pro and I wasnt sure what I was going to do, said Holland. My mom had suggested getting an Electrolux vacuum cleaner job. Then a couple days later Jim Devellano called and offered me the job as a scout for the Detroit Red Wings, and here I am today getting the call from Lanny and being with this incredible class of the 2020 induction. Funny how life goes.

The rest is hall-of-fame-worthy history. Holland took on his new role as scout with the Red Wings in 1985, then after helping the Wings win the 1997 Stanley Cup as an assistant general manager, was promoted to GM in Detroit. He went on to win the Cup three more times in 1998 for back-to-back titles, then again in 2002 and 2008 while winning more combined regular season and playoff games than any other NHL team during the stretch.

In May of 2019, Holland opted to part ways with the Red Wings after 22 years, and returned to Alberta to take on his role as general manager and president of hockey operations for the Oilers.

I was so fortunate that we had so many great players (in Detroit), and to work with Scotty Bowman and Jim Devellano and Mike Babcock, the list goes on and on, of talented people that I got to work with. Jim Nill running the draft, he said. I feel incredibly fortunate today, but I also know that I received the call from Lanny today and really there were so many people who did all the work in Detroit. I got to go up to the mic and make some announcements, but there were a lot of people who were doing the work.

You must be logged in to post a comment.

Continued here:

Holland recalls his 'greatest years' in the Hat - Medicine Hat News

Philadelphia is riddled with problems. We know this, of courseits what guided the creation of The Philadelphia Citizen and its focus on championing solutions.

In a fascinating conversation on Wednesday night between Citizen co-founder Larry Platt and Penn Medicine Chief Innovation Officer Roy Rosin, it became apparent to the nearly 250 guests in attendance that you cant solve any problemwhether its reinventing razors or tackling the challenges of a pandemicwithout asking the right questions, and corralling the right experts.

[People] cant reveal to you the solution very often. You have to get deeply embedded and just see everything and see all the things that they cant articulate or cant remember or are not even aware of, Rosin said. Once you get that deep into what the problem is, you can generate a whole bunch of different directions.

Over the course of the hour-long event, Rosin made clear that he believes deeply in the potential for Penn Medicineand the people who work thereto solve some of the biggest obstacles facing our city, including most recently when the Covid-19 pandemic hit.

From the time I walked in the door at Penn eight years ago, what I found consistently were people who support the idea of making things better, he said. These are mission-driven individuals who want to make the world a better place.

If you missed the chat, you can watch the full interview here (weve even edited out the technical glitches!). Or keep reading to find a handful of the many insightful takeaways we gleaned from the man Platt once dubbed the smartest person in Philadelphia you havent heard of.

1. He focuses on how not can

On innovating, Rosin said its more transformative to ask how can we do something, versus can we do this. When you ask the latter, youre likely to get a nobut when you ask how, you open the door to progress. If thats not a mantra we should all adopt, what is?

2. Hes got passion in spades.

Its clear that passion and compassion drive Rosins work. Yes, he has a Harvard degree in economics, an MBA from Stanford and nearly two decades of experience in Silicon Valley under his belt. But the health care sphere is so clearly where hes meant to be.

Just one example: When an event attendee asked Rosin for insight on how to improve doctor-patient communication, Rosin talked about the importance of finding the right doctor, making sure the time spent together is being used well, being part of a health care system where doctors use electronic consults during office visits to connect with specialists (and thereby fast-track the answer-getting process for patients).

And he acknowledged that theres no silver bullet to solving the problem. When the questioner divulged that she personally lived with health issues related to a rare birth defect, he offered to talk to her after the event to help her find a Penn doctor who could help. It was a poignant moment, the likes of which you dont typically see in online events with experts.

I dont want to oversimplify, he said. When you have a complex chronic disease [] it really takes a special person to work with you and work with you carefully. Luckily the clinicians I work with are these wonderful, mission-driven people who put in the nights and weekends to do that kind of thing. You find the right one, and great things happen. [There are] people who are just brilliant physicians, and Ill see if I can connect you with one of those people.

3. No crazy ego here.

Rosin took advantage of every opportunity to credit his Penn colleagues and sing their praises, over his. Its an admirable leadership trait, and one that Rosin mightve picked up during the 18 years he worked at Intuit under the tutelage of legendary leaders like Scott Cook and the late Bill Campbell.

Bill was an incredible leader, he was an incredible people person. And I think his success in some ways was because so much of business is about humans. Business is fundamentally human. [] Any one of us wouldve followed him up any mountain that he told us to charge. He made us feel special, he made us feel important, he paid attention to me before I deserved it, he said

4. Hes not an early tech adopter.

He may have the word innovation in his title but, no, he doesnt have every new gadget, or robots serving him meals at home.

Im like the last person to adopt new technology nowadays, he said, conceding that hes the only member of his team not on Slack. (I probably drive my team crazy not being on it.) But, as he explains in the video, an advantage to being somewhat of, well, a luddite:

One of the things that I actually think helped me in Silicon Valley was my ignorance. I was willing to ask dumb questions. Im willing to say when I dont understand things. I frequently dont understand things. But I try to think through them logically and try to make sense of it, and being a non-expert actually helps people who are truly experts to sometimes step back and say wait a minute, Im seeing that through a new lens, Im seeing that through new eyes, he said. Sometimes it is that ability to be a little bit behind that doesnt harm you so much and it does sort of start an interesting conversation.

And even though he doesnt have the glitziest toys, he of course appreciates and celebrates technology. I think technology is the only way we really scale innovation. Its very hard to scale new things without technology underneath it. So Im obviously a big fan of technology.

5. He believes the word innovation is hackneyed.

Its probably the most overused word out there these days. Its one of those words that because it now means everything, it means nothing, he said. I find myself being drawn more to terms like creative problem-solving than innovation just because it is such a beaten-up, overused word nowadays.

And he made clear that the way to creatively solve for any problem is to start by listening. Deeply.

Read this article:

Five things we learned from Penn Medicine innovation guru Roy Rosin - The Philadelphia Citizen

Covid-19 is a new disease and there is no drug or vaccine for it as of now and the patients are being given medicines that were approved for treating other viral infections. At least five medicines have either been given a go-ahead from the government to treat coronavirus infected patients in India or are in the final stages of the trial being carried out. India has also been using hydroxychloroquine (HCQ), an antimalarial drug, for treating Covid patients. Coronavirus positive cases in India are increasing at an alarming rate. With the highest single-day spike of 16,922 cases on Thursday, India's Covid-19 count reached 4,73,105. It is the fourth worst affected country, only behind USA, Brazil and Russia.

The treatment protocols for coronavirus are being revised from time to time based on emerging evidences. Here are the drugs, treatment presently available for coronavirus (Covid-19) and what we so far know about them:

1) Hydroxychloroquine (HCQ): It was first developed in India for the treatment of malaria. Two Indian firms, Ipca Laboratories and Zydus Cadila Ltd, are the worlds largest manufacturers of the drug. The Indian Council of Medical Research has also been using the drug to prevent infection among healthcare workers based on theoretical evidence that hydroxychloroquine does not allow the novel coronavirus, or SARS-COV2, to attach to cells. HCQ was touted as a potential coronavirus treatment by US President Donald Trump and some other global political leaders.

2) Covifor: The Drug Controller General of India (DCGI) has given approval to Hetero for manufacturing Remdesivir for the treatment of Covid-19. Heteros generic version of Remdesivir will be marketed under the brand name Covifor in India. It has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children, hospitalized with severe symptoms of the disease. Covifor (Remdesivir) will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner.

3) Fabiflu: Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of mild to moderate Covid patients. Priced at 103 per tablet, the prescription-based drug will be available as a 200 mg tablet at an MRP of 3,500 for a strip of 34 tablets.

4) Cipremi: Cipla has launched its own remedesivir under the name of Cipremi. Cipla said it will be commercialising remdesivir through its own facilities and partnered sites. The drug will be supplied through government and open market channels, to ensure equitable distribution. The drug is most effective on those who need oxygen support. Cipla is yet to disclose the pricing for the drug.

5) Methylprednisolone: Indian doctors have been successfully using Methylprednisolone in handling moderate to severe cases of the disease. It reduces its overall mortality and is a more essential part of the treatment regimen. Also, it reduces the severity of symptoms, doctors claimed. Dexamethasone is supported by a large trial and is a cost-effective drug. It is of the same group as Methylprednisone.

Subscribe to newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Original post:

Covid-19 treatment: Medicines being used for treating coronavirus patients in India - Livemint

By MO CRANKER on June 26, 2020.

mcranker@medicinehatnews.com

Classes this fall at Medicine Hat College are going to look much different compared to previous years.

College faculty members are preparing classes to be delivered in a combination of in-person and online formatting.

Weve been working for the last five or six weeks to figure out how exactly we will deliver our programs in the fall, said vice president academic and provost Vicky Roy. Weve been working hard with faculty and management to determine how many students we can have in classes for certain courses.

Roy says a number of classes will be shifted to an online format, while others have a mix of online and in-person learning.

Something like business, we are able to offer online this fall, she said. A health-care or nursing program, or something in the trades will be more of a blended format. We want practical components to be face-to-face when it is safe.

Roy says faculty is doing its best to make the fall semester happen.

Teachers are working really hard to get everything online, she said. We want to make sure all of the programs are student-friendly, flexible and inclusive.

Of course this is a challenging time, but we are prepared to deliver education in the fall.

More information on fall class formatting can be found on the MHC website under the Programs tab.

Program rollout for the winter will be evaluated at a later date.

You must be logged in to post a comment.

Read more from the original source:

MHC likely going part online, part in person - Medicine Hat News

Global Legal Marijuana Market Report is an objective and in-depth study of the current state aimed at the major drivers, market strategies, and key players growth. The study also involves the important Achievements of the market, Research & Development, new product launch, product responses and regional growth of the leading competitors operating in the market on a universal and local scale. The structured analysis contains graphical as well as a diagrammatic representation of worldwide Legal MarijuanaMarket with its specific geographical regions.

[Due to the pandemic, we have included a special section on the Impact of COVID 19 on the @ Market which would mention How the Covid-19 is Affecting the Global Legal Marijuana Market

Get sample copy of report @jcmarketresearch.com/report-details/52274/sample

** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with you.

Global Legal Marijuana(Thousands Units) and Revenue (Million USD) Market Split by Product Type such as Indoor Indoor Greenhouse

The research study is segmented by Application such as Laboratory, Industrial Use, Public Services & Others with historical and projected market share and compounded annual growth rate.Global Legal Marijuana by Region (2019-2028)

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Legal Marijuanain these regions, from 2012 to 2022 (forecast), covering

Additionally, the export and import policies that can make an immediate impact on theGlobal Legal Marijuana Market. This study contains a EXIM* related chapter on the Legal Marijuanamarket and all its associated companies with their profiles, which gives valuable data pertaining to their outlook in terms of finances, product portfolios, investment plans, and marketing and business strategies. The report on theGlobal Legal Marijuana Marketan important document for every market enthusiast, policymaker, investor, and player.

Key questions answered in this report Data Survey Report 2028

What will the market size be in 2022 and what will the growth rate be?What are the key market trends?What is driving Global Legal Marijuana Market?What are the challenges to market growth?Who are the key vendors inspace?What are the key market trends impacting the growth of theGlobal Legal Marijuana Market?What are the key outcomes of the five forces analysis of theGlobal Legal Marijuana Market?

Get Interesting Discount with Additional Customization@jcmarketresearch.com/report-details/52274/discount

There are 15 Chapters to display theGlobal Legal Marijuana Market.

Chapter 1, to describe Definition, Specifications and Classification ofLegal Marijuana, Applications of Legal Marijuana, Market Segment by Regions;

Chapter 2, to analyze the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis ofLegal Marijuana, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Legal MarijuanaSegment Market Analysis by Indoor Indoor Greenhouse ;

Chapter 7 and 8, to analyze the Legal MarijuanaSegment Market Analysis (by Application) Major Manufacturers Analysis of Legal Marijuana;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Indoor Indoor Greenhouse , Market Trend by Application Recreational Medical ;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyze the Consumers Analysis of Legal Marijuana;

Chapter 12, to describe Legal MarijuanaResearch Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Legal Marijuanasales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Select license versionand Buy Full Research Report: @jcmarketresearch.com/checkout/52274

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:JCMR global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact Us:JCMARKETRESEARCHJay (Marketing Manager)Phone:+1 (925) 478-7203Email:[emailprotected]

See the article here:

Legal Marijuana Market to Witness Huge Growth by 2028 | Medicine Man, Canopy Growth, Aphria - Cole of Duty

Researchers at UBCs faculty of medicine have received a combined total of $13.8 million in grants in the latest round of funding from the federal government in support of research aimed at addressing the health challenges of the COVID-19 pandemic.

In total, 19 teams at UBC working in drug research, global health, obstetrics, medical imaging, public health, and Indigenous health are receiving support as part of a $109-million investment in research projects by the federal government, focused on accelerating the development, testing, and implementation of measures to mitigate the rapid spread of COVID-19 and its negative consequences on people, communities, and health systems. Among the 19 UBC projects, 17 are being led by researchers from the faculty of medicine.

This new federal investment will enable UBC researchers to further contribute valuable insights into medical and societal responses to COVID-19, said Gail Murphy, vice-president, research and innovation at UBC. These research projects, which range from developing treatments to addressing the impacts of COVID-19 on vulnerable and marginalized populations, could have national and global impacts, and we are grateful for this support.

The UBC-led projects being supported by this funding range from the creation of an integrated rapid-response network for emergency departments across Canada and the development of genetic libraries, to research into the dual health emergencies of overdose and COVID-19 and studies into the long-term effects of COVID-19 on brain health.

The Government of Canada is providing the funding for this research through CIHR and the International Development Research Centre (IDRC), in partnership with Alberta Innovates (AI), Michael Smith Foundation for Health Research (MSFHR), Research Manitoba (RM), Research Nova Scotia (RNS), Saskatchewan Health Research Foundation (SHRF), and the New Brunswick Health Research Foundation (NBHRF).

Research findings and data produced as a result of the funding will be shared rapidly and openly (in line with the joint statement on sharing research data and findings relevant to the novel coronavirus outbreak) to inform the global public health response and to help save lives.

Below is a list of the UBC faculty of medicine projects receiving funding:

An international consortium of researchers led by Dr. Artem Cherkasov, professor in the department of urologic sciences and senior scientist at the Vancouver Prostate Centre and the Vancouver Coastal Health Research Institute, and Dr. Franois Jean, associate professor in UBCs faculty of science department microbiology and immunology, is receiving $2.1 million from CIHR to use artificial intelligence to search for SARS-CoV-2 inhibitors among known drugs. They will work to identify antiviral drugs that can work synergistically with antiviral therapy remdesivir to boost its effectiveness and block SARS-CoV-2, similar to the drug cocktails used in treating HIV and hepatitis C infections. This research will be performed at UBC FINDER, one of the largest university-based containment level 3 facilities in the world, founded by Dr. Jean.

Dr. Pieter Cullis, a professor in the faculty of medicine at UBC and researcher at Djavad Mowafaghian Centre for Brain Health, is receiving $237,445 from CIHR towards developing an antibody therapy for COVID-19. The study will use lipid nanoparticles to carry genetic instructions for the antibody to the liver, resulting in the secretion of antibodies that target the SARS-CoV-2 virus. Dr. Cullis predicts that this therapy, which could protect healthcare workers from infection and treat patients infected with the virus, would be a candidate for clinical testing within one year.

A team led by Dr. Soren Gantt, associate professor and head of the division of infectious diseases in the department of pediatrics at the UBC, is receiving $450,635 from CIHR to study and track the household transmission of SARS-CoV-2 in Africa. His team will examine patterns of SARS-CoV-2 transmission among children and adults in an established cohort of >200 households in Nairobi, Kenya, to garner insight into the global COVID-19 pandemic, and guide public health interventions in resource-limited settings.

Dr. Kurt Haas, professor in the department of cellular and physiological sciences at UBC, is receiving $172,414 from CIHR to examine how different genetic variants of the human ACE2 protein interact with the spike protein on the COVID-19 virus, SARS-CoV-2. Researchers in the Djavad Mowafaghian Centre for Brain Health will create genetic libraries of ACE2 variants, and test how the SARS-CoV-2 binds to them, which is how it infects host cells. Results may identify genetic contributions to disease expression, and this library will be available to test emerging drug therapies and aid efforts to develop novel therapeutics.

Dr. Corinne Hohl, associate professor in the department of emergency medicine and scientist at the Centre for Clinical Epidemiology and Evaluation and the Vancouver Coastal Health Research Institute, is receiving $2.5 million from CIHR to develop national standardized data collection, assessment and treatment protocols for COVID-19 in emergency departments. The ED Network will harmonize data collection across Canada and develop, evaluate and implement clinical decision rules for COVID-19 patients in emergency departments. The project is also receiving $250,000 from Genome BC and $75,000 from the BC Academic Health Sciences Network.

A team led by Dr. Rodney Knight, assistant professor in the department of medicine, is receiving $187,064 from CIHR to examine how public health measures, such as social distancing, affect the longer-term social and health of youth under 30. Researchers in Canada and France will use a range of research methods to document how policy and program responses can be optimized the improve the lives of youth in both countries.

Dr. Michael Law, director of the Centre for Health Services and Policy Research and professor in the School of Population and Public Health, is receiving $341,941 from CIHR to co-lead a study aimed at reducing the impact of COVID-19 in resource-poor countries. Working with Partners In Health, the researchers will use health information systems to monitor for potential COVID-19 hotspots and monitor changes in health services use in Haiti, Lesotho, Liberia, Malawi, Mexico, Rwanda, and Sierra Leone. This data will be used to help inform national public health responses to mitigate the spread of COVID-19.

Dr. Teresa Liu-Ambrose, professor in the department of physical therapy at UBC and researcher at the Vancouver Coastal Health Research Institute, is receiving $722,703 from CIHR to investigate the possible impact of COVID-19 on cognition and the brain post-infection. To achieve this, she will be measuring both cognitive function and acquire brain scans from Canadians aged 55 to 80 years, enrolled in the Canadian Longitudinal Study on Aging. Researchers will compare the cognitive function, brain structure, and brain function of adults with suspected or confirmed COVID-19 with those who are symptom-free or who have tested negative.

A team led by Dr. Deborah Money, professor in the department of obstetrics and gynaecology, is receiving $825,367 from CIHR for CANCOVID-Preg, a surveillance study into maternal and infant outcomes among pregnant women with COVID-19. The nation-wide research will be conducted by teams working in provinces and territories across Canada, and will allow Canada to develop urgently needed, evidence-based recommendations for maternity and pediatric care providers, as well as pregnant women and their families. Researchers will also contribute data to international collaborations, allowing for more comprehensive global understanding of COVID-19 in pregnancy.

Dr. Alice Mui, associate professor in the departments of surgery and biochemistry and molecular biology and researcher at the Vancouver Coastal Health Research Institute, is receiving $150,072 from CIHR to investigate why some patients with COVID-19 experience a surge of inflammatory proteins, called a cytokine storm, that can contribute to the development of acute respiratory distress. Her team will investigate whether the SARS-Co-V2 virus blocks the function of an anti-inflammatory cytokine called interleukin-10 in the body. Her team will also assess whether a compound they have developed can mimic the action of this cytokine and reduce inflammation in patients infected with the COVID-19 virus.

A team led by Dr. Josef Penninger, professor in UBCs faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC, is receiving $578,090 from CIHR to support Phase 2 trials of a promising antiviral therapy. The trials will involve using doses of human recombinant soluble ACE2 (hrsACE2) as a decoy for the SARS-CoV-2 virus, which enters human cells by attaching to the ACE2 receptor protein. This treatment could also protect organs including lung, heart, blood vessels and kidney from injury due to high doses of antiviral therapies such as remdesivir and chloroquine.

Dr. James Russell, professor in the UBC department of medicine, is receiving $3.5 million from CIHR for a multi-site randomized controlled trial (RCT) to study the safety and effectiveness of using losartan, a drug commonly used to treat high blood pressure and diabetes, to lower COVID-19 mortality. Losartan is in a class of drug known as an ARBs, which have been shown to reduce viral load and lung injury in influenza pneumonia.

A team led by Dr. Amanda Slaunwhite, senior scientist with the BC Centre for Disease Control and an adjunct professor in the School of Population and Public Health, is receiving $777,439 from CIHR and $75,000 from the Michael Smith Foundation for Health Research. The researchers will assess the impact of the new risk-mitigation guidance that permits prescribing of pharmaceutical alternatives to the toxic drug supply. Researchers will determine the effects of the pandemic and risk mitigation measures on COVID-19 infection, continuity of care for treatment of substance use disorders and non-fatal and fatal overdose in BC. The researchers will also identify barriers and facilitators to implementation from the perspectives of people who use substances, prescribers, harm reduction workers, and other providers and community members.

The team is led by principal investigators at UBC, the Canadian Institute for Substance Use Research (CISUR) at the University of Victoria (Dr. Bernie Pauly and Dr. Karen Urbanoski) and Simon Fraser University (Dr. Bohdan Nosyk and Dr. Natt Hongdilokkul). The team includes co-investigators and collaborators from the First Nations Health Authority, Ministry of Mental Health and Addictions, BC Centre on Substance Use, the BCCDC-based Compassion Inclusion and Engagement (CIE) (PEEP) peer network, Provincial Health Services Authority, BC-Yukon Association of Drug War Survivors and Public Health Agency of Canada.

A team of Indigenous and allied researchers governed by the Cedar Project Partnership and led by Dr. Patricia Spittal, professor in the UBC School of Population and Public Health, is receiving $549,258 from CIHR for a year-long study into the impacts of COVID-19 among Indigenous people who use drugs. Researchers will also roll out and test a bundle of virtual supports using an existing technology platform to mitigate and manage the impacts of COVID-19 on this population. The study will run as part of the Cedar Project, which, since 2003, has examined connections between impacts of colonization and intergenerational trauma on HIV and hepatitis C virus among young Indigenous people who use drugs in Vancouver and Prince George. The Cedar Project is one of the only research studies that continued operating during the early stages of the COVID-19 outbreak, and will draw on its existing trust-based relationships with over 800 Indigenous people in both cities.

A team led by Dr. Natalie Strynadka, professor of biochemistry in the department of biochemistry and molecular biology, is receiving $403,065 from CIHR to lead research in the development of antiviral treatments for COVID-19 using molecular structure-based drug design. Working with professor Mark Paetzel at Simon Fraser University, professor David Baker at University of Washington and a long-time U.S. pharmaceutical partner, these researchers will assess and design drugs that inhibit processing enzymes active during viral reproduction, an approach that has been successfully used to develop antiviral treatments for HIV and other global viral infections.

Dr. Teresa Tsang, cardiologist, director of the VGH and UBC Echo Lab and professor of medicine at UBC, is receiving $260,326 from CIHR to lead a multi-centre study that will use ultrasound imaging and Big Data to enhance the accuracy of COVID-19 diagnosis and patient prognostication. Researchers will use point-of-care heart-lung ultrasound imaging in addition to nasal swab testing, and collaborate with UBC engineering professor Purang Abolmaesumi to develop AI methods that will enhance the sensitivity of COVID-19 detection.

A team led by Dr. Annalee Yassi, Canada Research Chair in Global Health and Capacity-Building in UBCs School of Population and Public Health, is receiving $410,256 from IDRC. Her team will work with collaborating organizations in Vancouver, B.C. and Guateng, South Africa to analyze what works to protect healthcare workers in Canada and South Africa from COVID-19. They will also draw on survey research on the protection of healthcare workers in other countries to help inform international policy and practice on protecting healthcare workers caring for patients with COVID-19.

A version of this story originally appeared on UBC News.

Go here to read the rest:

UBC faculty of medicine researchers receive nearly $14M in federal funding for COVID-19 research - UBC Faculty of Medicine

Medicine Automated Dispensing Cabinets Market 2020

This report studies the Medicine Automated Dispensing Cabinets Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Medicine Automated Dispensing Cabinets Market analysis segmented by companies, region, type and applications in the report.

The major players covered in Medicine Automated Dispensing Cabinets Market BD, Omnicell, Takazono, TOSHO, Willach Group, YUYAMA, Aesynt, Cerner, Healthmark, KRZ, MTS Medication Technologies, S&S Technology, Beldico Integrated Solution, Swisslog, and TCGRx

The final report will add the analysis of the Impact of Covid-19 in this report Medicine Automated Dispensing Cabinets industry.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-medicine-automated-dispensing-cabinets-market-research-report-2018-one?utm_source=3wnews&utm_medium=36

Medicine Automated Dispensing Cabinets Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. Medicine Automated Dispensing Cabinets Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Research objectives:

To study and analyze the global Medicine Automated Dispensing Cabinets market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of Medicine Automated Dispensing Cabinets market by identifying its various sub segments.

Focuses on the key global Medicine Automated Dispensing Cabinets players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Medicine Automated Dispensing Cabinets with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Medicine Automated Dispensing Cabinets submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The Medicine Automated Dispensing Cabinets Market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Table of Contents: Medicine Automated Dispensing Cabinets Market

Chapter 1: Overview of Medicine Automated Dispensing Cabinets Market

Chapter 2: Global Market Status and Forecast by Regions

Chapter 3: Global Market Status and Forecast by Types

Chapter 4: Global Market Status and Forecast by Downstream Industry

Chapter 5: Market Driving Factor Analysis

Chapter 6: Market Competition Status by Major Manufacturers

Chapter 7: Major Manufacturers Introduction and Market Data

Chapter 8: Upstream and Downstream Market Analysis

Chapter 9: Cost and Gross Margin Analysis

Chapter 10: Marketing Status Analysis

Chapter 11: Market Report Conclusion

Chapter 12: Research Methodology and Reference

Key questions answered in this report

What will the market size be in 2026 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Inquire More about This https://www.reportsandmarkets.com/enquiry/global-medicine-automated-dispensing-cabinets-market-research-report-2018-one?utm_source=3wnews&utm_medium=36

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Link:

Impact of COVID-19 Outbreak on Medicine Automated Dispensing Cabinets Market to Witness BD, Omnicell, Takazono, TOSHO, Willach Group - Cole of Duty

The global Herbal Medicine Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Herbal Medicine Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Herbal Medicine Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Herbal Medicine Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Herbal Medicine Market.

Leading players of the global Herbal Medicine Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Herbal Medicine Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Herbal Medicine Market. It also provides useful recommendations for new as well as established players of the global Herbal Medicine Market.

Final Herbal Medicine Report will add the analysis of the impact of COVID-19 on this Market.

Herbal Medicine Market competition by top manufacturers/Key player Profiled:

TsumuraArizona NaturalWeledaSchwabeSIDO MUNCULMadausHerbal AfricaArkopharmaBlackmoresDaburNature HerbsTongrentangNatures AnswerZhongxinImperial GinsengZandBio-BotanicaTASLYYunnan BaiyaoPottersKunming PharmaHaiyaoTaijiGuangzhou PharmaSanjiuJZJT

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2354202

The research team projects that the Herbal Medicine market size will grow from XXX in 2019 to XXX by 2026, at an estimated CAGR of XX. The base year considered for the study is 2019, and the market size is projected from 2020 to 2026.

Segmentation by Product:

Detoxification MedicineAntipyretic MedicineAigestant MedicineBlood Circulation MedicineOthers

Segmentation by Application:

Western HerbalismTraditional Chinese MedicineOthers

Competitive Analysis:

Global Herbal Medicine Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Herbal Medicine Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Herbal Medicine Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

Key Questions Answered:

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2354202

Table of Contents

Report Overview:It includes major players of the global Herbal Medicine Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Herbal Medicine Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Herbal Medicine Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Herbal Medicine Market by application, it gives a study on the consumption in the global Herbal Medicine Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Herbal Medicine Market are profiled in this section. The analysts have provided information about their recent developments in the global Herbal Medicine Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Herbal Medicine Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Herbal Medicine Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Herbal Medicine Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Continue reading here:

Global Covid-19 impact on Herbal Medicine Market : What are the key opportunities? - 3rd Watch News

Animal Internal Medicine Market Overview 2020 2026

The risingtechnology in Animal Internal MedicineMarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/79752

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Key Competitors of the Global Animal Internal Medicine Market are: , Boehringer Ingelheim, Zoetis, Merck, Elanco, Bayer, Virbac, Ceva Sante Animale, Vetoquinol, Bimeda Animal Health, Chanelle

Historical data available in the report elaborates on the development of the Animal Internal Medicine on national, regional and international levels. Animal Internal Medicine Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:TabletPowder

Major Applications of Animal Internal Medicine covered are:LivestockPetsMarine Animal

This study report on global Animal Internal Medicine market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://reportsinsights.com/discount/79752

The fundamental purpose of Animal Internal Medicine Market report is to provide a correct and strategic analysis of the Animal Internal Medicine industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Animal Internal Medicine market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://reportsinsights.com/industry-forecast/Animal-Internal-Medicine-Market-79752

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Read the original here:

Animal Internal Medicine Market Detailed Analysis Of Current Industry Figures With Forecasts Growth By 2026 - 3rd Watch News

UNAIDS study shows that the impact on production and logistics caused by COVID-19 could have a significant effect on antiretroviral therapy supply worldwide, but steps taken now could lessen the damage done

GENEVA, 22 June 2020 A new analysis by UNAIDS has revealed the potential impacts that the COVID-19 pandemic could have in low- and middle-income countries around the world on supplies of the generic antiretroviral medicines used to treat HIV.

The UNAIDS survey discovered that the lockdowns and border closures imposed to stop COVID-19 are impacting both the production of medicines and their distribution, potentially leading to increases in their cost and to supply issues, including stock-outs over the next two months.

It is vital that countries urgently make plans now to mitigate the possibility and impacts of higher costs and reduced availability of antiretroviral medicines, said Winnie Byanyima, Executive Director of UNAIDS. I call on countries and buyers of HIV medicines to act swiftly in order to ensure that everyone who is currently on treatment continues to be on it, saving lives and stopping new HIV infections.

Since 24.5 million people were on antiretroviral therapy at the end of June 2019, millions of people could be at risk of harmboth to themselves and others owing to an increased risk of HIV transmissionif they cannot continue to access their treatment. A recent modelling exercise estimated that a six-month disruption of antiretroviral therapy in sub-Saharan Africa alone could lead to 500 000 additional AIDS-related deaths.

The production of antiretroviral medicines has been affected by several factors. Air and sea transport is being severely curtailed, hampering the distribution of the raw materials and other products, such as packaging material, that pharmaceutical companies need to manufacture the medicines. Physical distancing and lockdowns are also restricting the levels of human resources available in manufacturing facilities. The combined result of shortages of materials and workforces could lead to supply issues and pressure on prices in the coming months, with some of the regimens for first-line treatment and those for children projected to be the severest hit.

An array of circumstances are conspiring to add pressure on the overall cost of finished antiretroviral medicines. Increased overhead and transport costs, the need for alternative sourcing of key starting materials and active pharmaceutical ingredients and currency fluctuations caused by the forecasted economic shock are combining to push up the cost of some antiretroviral regimens. It has been estimated that a 1025% increase in these could result in an annual increase in the final cost of exported antiretroviral medicines from India alone of between US$ 100 million and US$ 225 million. Considering that in 2018 there was an HIV financing shortfall of more than US$ 7 billion, the world cannot afford an added burden on investments in the AIDS response.

UNAIDS and partners are working to mitigate the impact. The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) is providing immediate funding of up to US$ 1 billion to help countries to respond to COVID-19 and is expanding the use of its procurement platform to non-Global Fund recipients. The United States Presidents Emergency Plan for AIDS Relief is promoting continuity of HIV care, implementing new strategies, such as telemedicine, and allowing some programme flexibility in reporting requirements, staffing and funding re-allocation. The World Health Organization is compiling, exchanging and analysing information on HIV services that have been impacted and is liaising with manufacturers of antiretroviral medicines for emergency supply and with countries to switch to available quality alternative products and on possible mitigation measures. UNAIDS has been coordinating efforts to address the procurement and supply management challenges of antiretroviral therapy caused by the COVID-19 response.

However, a series of policy recommendations on the coordinated action that should be taken by governments and suppliers in order to resolve these issues map out how to minimize the impacts on supply chains and prices. By managing effectively current and future stocks of antiretroviral medicines, supply can be continued for all who need treatment.

The UNAIDS analysis collected information from the eight generic manufacturers of antiretroviral medicines in India that together account for more than 80% of generic antiretroviral medicine production worldwide. Government departments in seven other countries that produce generic antiretroviral medicines and that account for most of the production of generic antiretroviral medicines in low- and middle-income countries domestically were also surveyed.

Read the original here:

COVID-19 could affect the availability and cost of antiretroviral medicines, but the risks can be mitigated - UNAIDS

Regenerative Medicine Market: Snapshot

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe areVericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc.A large number of players are anticipated to enter the global market throughout the forecast period.

See the original post here:

Regenerative Medicine Market Analysis Growth Demand, Key Players, Share Size, and Forecast To 2025 - 3rd Watch News

By RYAN MCCRACKEN on June 26, 2020.

rmccracken@medicinehatnews.com

The Medicine Hat Cubs will not be icing a team this season.

The local junior B hockey club made the announcement in a Thursday release, stating financial concerns brought on by the pandemic, particularly diminishing sponsorship revenues, have forced a one-year hiatus from the Heritage Junior Hockey League.

The sponsors that we did have, they more or less asked for a year off due to COVID-19, said Cubs president Richard Fritzler. Unless things change if there is a season or half a season, if we do get a sponsor or something we would probably look at it. But right now, the way things stand, no.

Fritzler added the Cubs will not be penalized for the decision, as HJHL teams were given the ability to opt out of the season without consequence should they experiencing financial hardship.

Well take the season off to regroup, said Fritzler. Were looking at a couple options (for next year) that I cannot reveal right now.

HJHL president Gilbert Renaud says the league is still planning to go ahead with its 2020-21 season in accordance with Hockey Alberta and Alberta Health guidelines. As of Thursday, Medicine Hat was the first squad in the 14-team league to announce it was stepping away for the season.

We are looking forward to (a season). More than likely it will happen, what it looks like? Who knows, said Renaud, adding teams that opt out of the upcoming season will not be able to reserve players for 2021-22, but will face no other penalties. The Cubs, next year basically I believe all theyll be able to do is snag four 21-year-olds from other teams that are not keeping them, just like a new team.

The Cubs are coming off two of their strongest seasons in recent memory, having turned around a struggling ship over the past five years. They were even slated to host the Hockey Alberta Junior B Provincial Championships before COVID-19 forced its cancellation. The club has since parted ways with co-coaches JD Gaetan and Steve Leipert and had yet to hire replacements, but general manager and director of hockey operations Dave Kowalchuk and his scouting staff will remain with the task of rebuilding the team from the ground up.

All four scouts and myself are going to continue to do as we would if we were playing. The plan is to recruit and plan for next year. Its obviously going to make it difficult for us because were basically starting from scratch, said Kowalchuk. I think its a challenge, and Im excited for the challenge. Were not going to back down and were excited to come back next year.

As for players who had previously committed to return, Kowalchuk says theyll be encouraged to find new teams for the upcoming season, and if they wish to return to the Cubs in 2021 there will be a place on the roster.

Were never going to hold anyone back from going to play. I think thats with everybody in hockey, you want the kids to play and have fun and enjoy their junior hockey careers, said Kowalchuk. Itll be the next step for them to try to find a place, and well just do what we have to do to make a team for next year.

Kowalchuk added he believes the Cubs announcement is simply the first domino to fall, as he expects other teams and organizations will follow suit.

I know there are other teams in our league that are going to be in the same boat, but I think a lot of places are just kind of holding off and waiting to see what happens, he said. In the long term here, I think youre going to see a lot more teams packing it in, a lot more leagues closing up for a year, and I think thats smart.

You must be logged in to post a comment.

Visit link:

Cubs won't take the ice this season - Medicine Hat News

ANN ARBOR, MI Michigan Medicine will be laying off 738 employees by the end of the month, according to a spokesperson.

Last month, University of Michigan and hospital officials projected a loss of $230 million in the 2019-20 fiscal year and expect the losses to continue, and as a result, 1,400 employees would be furloughed or laid off. Michigan Medicine spokesperson Mary Masson said Thursday that Michigan Medicine achieved more than half of that target through attrition and furloughs, and the number has been reduced.

Michigan Medicine made safety in all our missions the top priority when determining where reductions in force would occur. These challenging but carefully considered actions will help Michigan Medicine continue to provide hope and healing to our patients and allow us to continue to support our clinical, educational and research missions, Masson said.

Masson added that these are eliminated positions and not furloughs, but employees are eligible for rehire any time during the layoff period.

A staff member laid off or transferred from a position will be recalled to the position before temporary or new regular staff members are hired if it occurs within set time limits and the staff member has retained the ability to perform the work, Masson said.

Masson said that some impacted employees would receive pay and beenfits for varying periods of time, depending on their tenure. All impacted employees will have access to career transition assistance, Masson said.

Michigan Medicine previously suspended merit salary increases, employer retirement match, tuition reimbursement and delay non-urgent capital projects, including plans for a 12-story adult hospital. The health care system has also implemented a hiring freeze on 300 vacancies in addition to furloughs, according to a May 5 news release.

Michigan Medicine to furlough 1,400 employees, delay construction on new hospital

The university announced in April that all three campuses, including Michigan Medicine, estimate anticipated losses of $400 million to $1 billion through the end of the 2020 calendar year. UM also announced hiring freezes and that employees base salaries would not increase through the end of the 2020-21 budget year.

University of Michigan imposes hiring, salary freezes to face anticipated losses of $400M to $1B

Visit link:

Michigan Medicine nearly cuts layoffs in half; 738 employees to be cut by end of June - MLive.com

WESTFIELD, N.J., June 22, 2020 /PRNewswire/ --The Core Message Of COVID-19 Is That Worldwide Capacity To Launch Bacterial & Viral Biological Warfare Has Arrived And We Are Not Only Virtually Defenseless Lacking Effective Vaccines, Drugs And Other Therapies But Disturbingly Unaware Of This Potential Threat. FIM, The Foundation For Innovation In Medicine, Proposes That A National Research Coalition Be Expeditiously Established Whose Mission Is Not To Discover Vaccines Or Drugs Or Biologicals But To Concentrate On The Basic Biological Mechanisms Of These Organisms Which Fundamental Scientific Information Has Enormous Value In Supporting Pharmaceutical, BioTech And Other Groups In Their Quests To Discover Effective Anti-viral, Anti-bacterial Or Other Therapies. After All, These Organisms Have, By Constant Evolutionary Adaptation Under The Most Adverse Environmental Conditions, Survived Over Billions Of Years. And, By Doing So, Have Evolved Multiple Mechanisms For Survival. Examples To Be Explored Are How Do Bacteria Protect Their Walls And How Do Viruses Mutate? We Must Recognize That This Challenging Mission Is Far Beyond The Capability Of Individual Companies, Government Institutions And Other Research Organizations.

But There Is Another Largely Unrecognized Hurdle Which Is Critical To Resolve. Once A Promising Therapy Is Identified In The Laboratory It Must Then Be Tested In Clinical Studies, The Critical Step In Medical Discovery. We, As A Longterm National Policy Primarily Based On Excessive Safety Concerns, Have Erected Enormous Barriers To Conduct Such Studies Resulting In Retarding Medical Discovery In General. FIM Proposes An Expeditious Doable Way To Reduce These Barriers. Make No Mistake About It And Let's Not Kid Ourselves, If Such Barriers Aren't Substantially Reduced The War Against Biological Warfare Will Be Inexcusably Retarded For Many Will Pay The Price.

A Broad Discussion Of The Social And Medical/Scientific Dynamics Surrounding The Threat Of Biological Warfare Is Presented.

COVID-19 and Beyond

Stephen L. DeFelice, M.D.

For more information about Dr. DeFelice and FIM, please contact Patricia Park at fimdefelice@aol.comor 908- 233- 2448.

View original content:http://www.prnewswire.com/news-releases/fim-the-foundation-for-innovation-in-medicine-proposes-that-a-national-research-coalition-be-expeditiously-established-to-address-covid-19-and-biological-warfare-301080677.html

SOURCE The Foundation for Innovation in Medicine (FIM)

Here is the original post:

FIM, The Foundation for Innovation in Medicine, Proposes That a National Research Coalition Be Expeditiously Established to Address COVID-19 and...

In recent years, Ive learned of wonderful aspects of Native American culture, especially the sacred medicine wheel or hoop of life with variations in colors and meanings according to each tribe and nation. The circle is a universal spiritual symbol, but the Native American medicine wheel has complexity and power for me, a person who has cared for the elderly throughout my lifetime on the prairie.

For centuries, the Native American medicine wheel has given bearing, a sense of position, an objective and simultaneous understanding of both the infinitude and the limitation of life. The wheel brings a conscious spirituality that recognizes and accepts all things. For me, it closes the gap between the cynical scientific part of me and the inclusive spiritual part. By spiritual, I mean that part of our soul that savors music, art, poetry and the divine; the part that grows to love all things living and nonliving.

In the following verse, Ive taken the liberty to express my interpretation of the sacred circle:

First we get down on our knees and feel the soil, sacred Mother Earth, the world around us, the animals, plants, prairies, lakes, mountains, the environment of our planet from where all food and sustenance comes; earth is foundation.

Then we stand and raise our arms to sacred Father Sky, the sun, stars, clouds, rain, wind, air and breath of life, light and dark; from where all energy flows and ebbs; sky is infinity.

Then we turn and bow east, symbolized by the color red, the rising sun, springtime, birth, the very young, a sense of innocence and hope for the future.

Then we bow south, symbolized by the color yellow, the full sun, summer, early adulthood, a sense of unconquerable power and the courage to fight for justice.

Then we bow west, symbolized by the color black, the setting sun, autumn, mature adulthood, a sense of gravity to protect freedom and face vulnerability with honest eyes.

Finally we bow north, symbolized by the color white, nighttime, winter, old age, wisdom to savor friendship, family and the circle of life, release from fear of change and death, and a sense of empathy from having walked in anothers moccasins.

We pray in harmony as love consoles. O sacred hoop of life, please touch our souls.

This essay is a composite of works written by the late Richard P. Holm, M.D. who died in March 2020 after a battle with pancreatic cancer. He was founder of The Prairie Doc and author of Lifes Final Season, A Guide for Aging and Dying with Grace available on Amazon. Dr. Holms legacy lives on through his Prairie Doc organization. For free and easy access to the entire Prairie Doc library, visit http://www.prairiedoc.org and follow Prairie Doc on Facebook, featuring On Call with the Prairie Doc a medical Q&A show streaming on Facebook most Thursdays at 7 p.m. Central.

Visit link:

The Native American medicine wheel | Health | willistonherald.com - Williston Daily Herald

Bacteria, as it turns out, are a lot like us. They get complacent in relaxed, non-threatening environments. And when theyre relaxed, they dont produce defenses that guard against things that want to kill them, like competing organisms or microbial predators.

But when threatened, bacteria produce a veritable army of molecular defenses. Drilling down into these defenses and the elicitors that trigger them has enabled scientists to discover antibiotics and antivirals, knowledge that might yet prove useful in the fight against the coronavirus.

Chen Zhang,agraduate student in theMohammadSeyedsayamdost lab, preparesa cell culture within a sterile clean hood.

Photo by

C. Todd Reichart, Department of Chemistry

Armed with recent funding from the National Institutes of Health (NIH) and Princeton University, Associate Professor of ChemistryMohammad Seyedsayamdost is engaging that fight with an approach called the High-Throughput Elicitor Screening (HiTES). First introduced by the Seyedsayamdost lab in 2014, the technology enables researchers to screen, identify and characterize the natural products that are biosynthesized only when bacteria are under threat.

Seyedsayamdost calls these cryptic natural products. They are the defenses Nature itself has devised to counter a certain threat.

More than half of the anti-infectives used clinically come from nature, from natural products synthesized by bacteria, fungi or plants, said Seyedsayamdost, a chemical biologist. These are small organic molecules synthesized and released into the environment where they carry out a variety of functions, one of which is chemical warfare against other organisms.

These molecules have been honed by evolution to kill a competitor or a virus, exactly the type of thing we want to do in medicine sometimes kill a pathogen. So, theyve been a great source of anti-infective agents.

Third-year graduate student Chen Zhang is working on the project with Seyedsayamdost, coupling HiTES screening with imaging mass spectrometry a proven method for the detection of small molecules to discover novel natural products, the biological activities of which can be tested against pathogenic bacteria or viruses like the agent of COVID-19.

In addition, first-year student Esther Han is combining the HiTES approach with antimicrobial activities to directly search for new and cryptic anti-infectives.

Since every compound has a unique mass signal (as fingerprints are to humans), comparing signals in untreated bacterial cultures to those in elicited cultures can easily identify new natural products only present in specific conditions, said Zhang. Once identified, follow-up studies can elucidate the biological activity and molecular target of the natural product.

Esther Han,agraduate student in the Seyedsayamdost lab, checkson cell cultures in an incubator.

Photo by

C. Todd Reichart, Department of Chemistry

The Seyedsayamdost lab has found that antibiotics themselves are the best elicitors, or, the best triggers for cryptic natural products. Old antibiotics, therefore, can be used to discover new, cryptic ones. This observation was first made with the bacterium Burkholderia thailandensis. In this instance, Seyedsayamdost found that a carefully calibrated Goldilocks dose of the antibiotic Trimethoprim not too much or it will kill the bacteria; not too little or the bacteria wont respond causes the bacterium to synthesize 21 of the 22 natural products that it encodes.

Burkholderia throws the kitchen sink at you if you treat it with low-dose Trimethoprim, said Seyedsayamdost.

Seyedsayamdost was motivated to deploy HiTES technology in the battle against COVID-19 as a way of meeting what he characterizes as the obligation of scientists.

If youre working in this research area and you have a chance to contribute even indirectly to a therapeutic, you have an obligation to do so. So from that point of view, I think its important to be engaged, Seyedsayamdost said.

The other issue is, infectious disease is going to be on the rise. We knew that at the beginning of the century, but this pandemic really drives the point home. This is something that academic scientists need to address, but big pharma needs to deal with, too, he added. Its unfortunate that big pharma has largely gotten away from finding treatments against infectious agents. But I think the coronavirus will be a wake-up call.

This research is supported by the NIH Director's New Innovator Award (DP2-AI-124786) and the Princeton Intellectual Property Accelerator Award.

See the article here:

Triggering bacteria in the service of medicine - Princeton University

SEATTLE, June 22, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine,a precision oncology company revolutionizing cancer diagnostics anddrug discoveryby pre-testing drugs on patient-derivedtumor-based organoids, today presentsdataonthe predictive value ofthe PARISTestinitsposter,Organoid-based functional test to predict personalized treatment in cholangiocarcinoma(poster board #818),duringthe 2020AACRVirtualMeetingbeingheldJune 22-24, 2020.

The PARISTest is a CLIA certifiedfunctional drug assay using tumor-derived organoids. By compiling assay results, the PARIS Test generatesan actionable report to oncologists as a tool for therapeutic decisions, ranking sensitivity to targeted, endocrine and chemotherapy agents.

Dr. Astrid Margossian, M.D, Ph.D., Chief Medical Officer at SEngine, presents their poster summarizingthe strong correlation between genomics,retrospective treatment outcomes and PARISTest drug sensitivity results based on a retrospective analysis ofcholangiocarcinomapatients.The poster also highlights encouraging data on positive prospective evidence from three patients who received a PARIS Test guided treatment, each with good clinical outcome correlation. Cholangiocarcinoma is a rare type of cancer with limited therapeutic options. SEngine has demonstrated utility of the PARIS Test as a tool for oncologists to design innovative therapeutic strategies for cholangiocarcinoma patients.

In addition to SEngines poster presentation, scientific leadership at the company lead the AACR Education Session Functional Precision Medicine: Techniques, Uses and Challenges on June 23, 2020. Christopher Kemp, Ph.D., Scientific Director at SEngine Precision Medicine and full member of the Fred Hutchinson Cancer Research Center, chairs the education session. Chief Executive Officer Dr. Carla Grandori, M.D., Ph.D., presents on the strong predictive value of the PARIS Test and provides key takeaways from five years running SEngines CLIA certified organoid-based drug sensitivity assay.

Details related to the poster presentation are as follows:Title: Organoid-based functional test to predict personalized treatment in cholangiocarcinomaLead Author:AstridMargossian, M.D.,Ph.D.Senior Author: CarlaGrandori, M.D.,Ph.D.Poster Board #: 818Poster Session: Translational Research with Targeted Therapies

Details related to the education session are as follows:Education Session: Functional Precision Medicine: Techniques, Uses and ChallengesChair: Christopher Kemp, Ph.D.Invited Speaker: Carla Grandori, M.D., Ph.D.Talk Title: Predictive value and lessons learned from the PARIS Test: a CLIA certified drug sensitivity assay employing patient-derived tumor organoids

About the PARIS TestThe PARISTest is based on the capability to propagate patient-specific cancercellsas organoidsoutside the bodyand is applicable to all solid tumorsincluding colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grownin 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics.For cancerswherea treatmentpath is not clear, such asmany metastatic and recurrent cancers,the PARIS Test provides crucial information to thetreating physicianstomatch the right drug to the right patient.

AboutSEnginePrecision MedicineSEnginePrecision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells.As a spin-out from the world-renowned Fred Hutchinson Cancer ResearchCenter,SEngineis leveraging over two decades of R&D in diagnostics and drug discovery. The Company is commercializingthePARISTest, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools.SEnginesCLIA certified PARISTest generates predictive drug sensitivity reports for patients with solid tumors.SEngineis also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies leveraging its precision oncology platform.

Discover more atSengineMedicine.comand follow the latest news fromSEngineon Twitter at@SEngineMedicineand onLinkedIn.

Contact:

Stephanie Carringtonstephanie.carrington@westwicke.com646-277-1282

See the original post here:

SEngine Precision Medicine Presents Innovative Data on the CLIA Certified PARIS Test for Oncology Drug Sensitivity and the Future of Functional...

COLUMBUS, Ohio--(BUSINESS WIRE)--Washington Prime Group Inc. (NYSE: WPG) today announced that the Company has signed a letter of intent with WVU Medicine to repurpose the former Sears location at Morgantown Mall, in Morgantown, West Virginia, as a logistics, distribution and fulfillment center serving the broader WVU Medicine network. This project and use are consistent with Washington Prime Groups recently launched Fulventory initiative, through which the Company is focused on providing innovative logistics and warehouse solutions at its venues centrally located in key markets across the US.

Lou Conforti, CEO and Director of Washington Prime Group stated: I am truly humbled to announce our affiliation with WVU Medicine at Morgantown Mall for a variety of reasons. First and foremost, their vision of transforming lives and eliminating health disparities is a charter we admire and have taken very seriously as illustrated by our ~500 community service projects via our WPG Cares charitable endeavors. Second, the logistics and warehouse utilization of the Morgantown Mall space by WVU Medicine further exhibits the viability of Fulventory, our recently initiated last mile fulfillment program. Last, but not least, I am officially submitting my name for consideration as the 68th Mountaineer mascotwith the understanding as a beardless flatlander hailing from Illinois, I am a longshot at best. We welcome our friends from West Virginia University and look forward to establishing a longstanding relationship.

Washington Prime Group launched Fulventory during the first half of 2020, an initiative which allows tenants to utilize space within the Companys assets for last mile fulfillment, including customized logistics and warehouse solutions, BOPIS (buy online and pickup in store), and inventory clearance. The Fulventory collateral material with additional information and conceptual renderings is available here.

About Washington Prime Group

Washington Prime Group Inc. is a retail REIT and a recognized leader in the ownership, management, acquisition and development of retail properties. The Company combines a national real estate portfolio with its expertise across the entire shopping center sector to increase cash flow through rigorous management of assets and provide new opportunities to retailers looking for growth throughout the U.S. Washington Prime Group is a registered trademark of the Company. Learn more at http://www.washingtonprime.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 which represent the current expectations and beliefs of management of Washington Prime Group Inc. (WPG) concerning the proposed transactions, the anticipated consequences and benefits of the transactions and the targeted close date for the transactions, and other future events and their potential effects on WPG, including, but not limited to, statements relating to anticipated financial and operating results, the Companys plans, objectives, expectations and intentions, cost savings and other statements, including words such as anticipate, believe, confident, plan, estimate, expect, intend, will, should, may, and other similar expressions. Such statements are based upon the current beliefs and expectations of WPGs management, and involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of WPG to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, without limitation: changes in asset quality and credit risk; ability to sustain revenue and earnings growth; changes in political, economic or market conditions generally and the real estate and capital markets specifically; the impact of increased competition; the availability of capital and financing; tenant or joint venture partner(s) bankruptcies; the failure to increase store occupancy and same-store operating income; risks associated with the acquisition, disposition, (re)development, expansion, leasing and management of properties; changes in market rental rates; trends in the retail industry; relationships with anchor tenants; risks relating to joint venture properties; costs of common area maintenance; competitive market forces; the level and volatility of interest rates; the rate of revenue increases as compared to expense increases; the financial stability of tenants within the retail industry; the restrictions in current financing arrangements or the failure to comply with such arrangements; the liquidity of real estate investments; the impact of changes to tax legislation and WPGs tax positions; losses associated with closures, failures and stoppages associated with the spread and proliferation of the coronavirus (COVID-19) pandemic; to qualify as a real estate investment trust; the failure to refinance debt at favorable terms and conditions; loss of key personnel; material changes in the dividend rates on securities or the ability to pay dividends on common shares or other securities; possible restrictions on the ability to operate or dispose of any partially-owned properties; the failure to achieve earnings/funds from operations targets or estimates; the failure to achieve projected returns or yields on (re)development and investment properties (including joint ventures); expected gains on debt extinguishment; changes in generally accepted accounting principles or interpretations thereof; terrorist activities and international hostilities; the unfavorable resolution of legal or regulatory proceedings; the impact of future acquisitions and divestitures; assets that may be subject to impairment charges; significant costs related to environmental issues; changes in LIBOR reporting practices or the method in which LIBOR is determined; and other risks and uncertainties, including those detailed from time to time in WPGs statements and periodic reports filed with the Securities and Exchange Commission, including those described under Risk Factors. The forward-looking statements in this communication are qualified by these risk factors. Each statement speaks only as of the date of this press release and WPG undertakes no obligation to update or revise any forward-looking statements to reflect new information, subsequent events or circumstances. Actual results may differ materially from current projections, expectations, and plans, if any. Investors, potential investors and others should give careful consideration to these risks and uncertainties.

Follow this link:

WVU Medicine to Open Fulfillment Location at Morgantown Mall as Part of Washington Prime Group's Fulventory Initiative - Business Wire

CHICAGO Chicago has a unique version of the SARS-CoV-2 virus. Local researchers have made a discovery that could help direct future vaccines and treatments.

Viruses change as they travel. Its their natural behavior and a trait scientists are tracking when it comes to SARS-CoV-2, the virus that causes COVID-19. Some of the changes are benign. Others are more critical when it comes to helping the virus spread and survive.

Northwestern Medicine researchers looked at samples from patients back in March. They found three different versions of the virus in circulation in Chicago.

One of those variants closely resembles the DNA sequence of samples found in China during the early days of the outbreak and hasnt been found in many other areas of the United States. The two other versions are similar to viral sequences found in New York and on the West Coast, particularly in Washington state.

Dr Egon Ozer is with Northwestern Medicine and assistant professor of medicine in the division of infectious disease.

Those that had the Chicago variant seem to have on average lower viral loads, less virus in their airways especially in the upper airways; the nose and throat, Ozer said. Compared to those viruses that were most closely related to New York strains. And then in terms of vaccine development knowing where these differences are and knowing, especially if we see some variants are becoming more dominant, it could help us target our vaccine development a lot more, in a more focused matter.

The researchers said there was no difference in patient outcomes or disease severity between the different mutations. And they said early signs point to the New York variant emerging as a more dominant strain.

Go here to see the original:

Northwestern Medicine finds 3 versions of COVID-19 in Chicago - WGN TV Chicago